The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Notice Regarding DMC Evaluation Results of the Phase 1/2 Clinical Trial of DFP-10917 in Combination with VEN
Open the original documentBreakdown of the overall response rate in the Phase 2 expanded cohort
3 cases of incomplete remission (CRi) and 3 cases of morphologic leukemia-free state (MLFS) (6 cases)
3 cases of incomplete remission (CRi), 3 cases of morphologic leukemia-free state (MLFS), and 3 cases of partial response (PR) (9 cases)
Because inquiries were received asking whether there was a discrepancy in, or a typographical error in, the overall response rate
| Item | Details |
|---|---|
| Disclosure subject to correction | Notice Regarding DMC Evaluation Results of the Phase 1/2 Clinical Trial of DFP-10917 in Combination with VEN |
| Original disclosure date | 25 March 2026 |
| Location of correction | Breakdown of the overall response rate in the Phase 2 expanded cohort |
| Details of correction | 3 cases of incomplete remission (CRi) and 3 cases of morphologic leukemia-free state (MLFS) (6 cases) → 3 cases of incomplete remission (CRi), 3 cases of morphologic leukemia-free state (MLFS), and 3 cases of partial response (PR) (9 cases)（53% (unchanged)） |
| Reason for correction | Because inquiries were received asking whether there was a discrepancy in, or a typographical error in, the overall response rate |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Inquiries were received asking whether there was a discrepancy in, or a typographical error in, the overall response rate reported in the disclosure dated 25 March 2026.